Literature DB >> 15295048

Loss of Smad3 in acute T-cell lymphoblastic leukemia.

Lawrence A Wolfraim1, Tania M Fernandez, Mizuko Mamura, Walter L Fuller, Rajesh Kumar, Diane E Cole, Stacey Byfield, Angelina Felici, Kathleen C Flanders, Thomas M Walz, Anita B Roberts, Peter D Aplan, Frank M Balis, John J Letterio.   

Abstract

BACKGROUND: The receptors for transforming growth factor beta (TGF-beta) and their signaling intermediates make up an important tumor-suppressor pathway. The role of one of these intermediates--Smad3--in the pathogenesis of lymphoid neoplasia is unknown.
METHODS: We measured Smad3 messenger RNA (mRNA) and protein in leukemia cells obtained at diagnosis from 19 children with acute leukemia, including 10 with T-cell acute lymphoblastic leukemia (ALL), 7 with pre-B-cell ALL, and 2 with acute nonlymphoblastic leukemia (ANLL). All nine exons of the SMAD3 gene (MADH3) were sequenced. Mice in which one or both alleles of Smad3 were inactivated were used to evaluate the role of Smad3 in the response of normal T cells to TGF-beta and in the susceptibility to spontaneous leukemogenesis in mice in which both alleles of the tumor suppressor p27Kip1 were deleted.
RESULTS: Smad3 protein was absent in T-cell ALL but present in pre-B-cell ALL and ANLL. No mutations were found in the MADH3 gene in T-cell ALL, and Smad3 mRNA was present in T-cell ALL and normal T cells at similar levels. In mice, the loss of one allele for Smad3 impairs the inhibitory effect of TGF-beta on the proliferation of normal T cells and works in tandem with the homozygous inactivation of p27Kip1 to promote T-cell leukemogenesis.
CONCLUSIONS: Loss of Smad3 protein is a specific feature of pediatric T-cell ALL. A reduction in Smad3 expression and the loss of p27Kip1 work synergistically to promote T-cell leukemogenesis in mice. Copyright 2004 Massachusetts Medical Society

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15295048     DOI: 10.1056/NEJMoa031197

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  57 in total

Review 1.  Transforming growth factor (TGF)-β pathway as a therapeutic target in lower risk myelodysplastic syndromes.

Authors:  Jan Philipp Bewersdorf; Amer M Zeidan
Journal:  Leukemia       Date:  2019-04-08       Impact factor: 11.528

2.  Transforming growth factor beta facilitates beta-TrCP-mediated degradation of Cdc25A in a Smad3-dependent manner.

Authors:  Dipankar Ray; Yasuhisa Terao; Dipali Nimbalkar; Li-Hao Chu; Maddalena Donzelli; Tateki Tsutsui; Xianghong Zou; Asish K Ghosh; John Varga; Giulio F Draetta; Hiroaki Kiyokawa
Journal:  Mol Cell Biol       Date:  2005-04       Impact factor: 4.272

3.  Smad3 reduces susceptibility to hepatocarcinoma by sensitizing hepatocytes to apoptosis through downregulation of Bcl-2.

Authors:  Yu-An Yang; Gen-Mu Zhang; Lionel Feigenbaum; Ying E Zhang
Journal:  Cancer Cell       Date:  2006-06       Impact factor: 31.743

Review 4.  TGF-β signaling and its targeting for glioma treatment.

Authors:  Jianfeng Han; Christopher A Alvarez-Breckenridge; Qi-En Wang; Jianhua Yu
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

5.  Inactivation of LEF1 in T-cell acute lymphoblastic leukemia.

Authors:  Alejandro Gutierrez; Takaomi Sanda; Wenxue Ma; Jianhua Zhang; Ruta Grebliunaite; Suzanne Dahlberg; Donna Neuberg; Alexei Protopopov; Stuart S Winter; Richard S Larson; Michael J Borowitz; Lewis B Silverman; Lynda Chin; Stephen P Hunger; Catriona Jamieson; Stephen E Sallan; A Thomas Look
Journal:  Blood       Date:  2010-02-01       Impact factor: 22.113

Review 6.  Single Nucleotide Polymorphism in SMAD7 and CHI3L1 and Colorectal Cancer Risk.

Authors:  Amal Ahmed Abd El-Fattah; Nermin Abdel Hamid Sadik; Olfat Gamil Shaker; Amal Mohamed Kamal
Journal:  Mediators Inflamm       Date:  2018-10-25       Impact factor: 4.711

7.  Berbamine inhibits proliferation and induces apoptosis of KU812 cells by increasing Smad3 activity.

Authors:  Yun Liang; Xi Qiu; Rong-zhen Xu; Xiao-ying Zhao
Journal:  J Zhejiang Univ Sci B       Date:  2011-07       Impact factor: 3.066

8.  Blockade of transforming growth factor-beta1 accelerates lymphatic regeneration during wound repair.

Authors:  Tomer Avraham; Sanjay Daluvoy; Jaime Zampell; Alan Yan; Yosef S Haviv; Stanley G Rockson; Babak J Mehrara
Journal:  Am J Pathol       Date:  2010-11-05       Impact factor: 4.307

9.  The endogenous ratio of Smad2 and Smad3 influences the cytostatic function of Smad3.

Authors:  Sang Gyun Kim; Hyun-Ah Kim; Hyun-Soon Jong; Jung-Hyun Park; Noe Kyeong Kim; Seung Hwan Hong; Tae-You Kim; Yung-Jue Bang
Journal:  Mol Biol Cell       Date:  2005-08-10       Impact factor: 4.138

10.  Betaglycan alters NFκB-TGFβ2 cross talk to reduce survival of human granulosa tumor cells.

Authors:  Maree Bilandzic; Simon Chu; Yao Wang; Han L Tan; Peter J Fuller; Jock K Findlay; Kaye L Stenvers
Journal:  Mol Endocrinol       Date:  2013-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.